1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Project Grant (Multiple awards found related to ribosome biogenesis) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). NIGMS consistently funds fundamental research on ribosome biogenesis, including projects focused on mechanistically characterizing human ribosome biogenesis, studying molecular structure and physical properties of ribosome assembly pathways, and regulating ribosomal RNA transcri…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Grants and Funding | National Institute of General Medical Sciences Keep on top of the latest status of changes impacting NIH grants administration and funding here . NIGMS places great emphasis on the support of individual, investigator-initiated grants within its scientific mission areas. Most grants are for research projects (R01/R35), but NIGMS also funds small business (SBIR/STTR) grants as well as some research resources.
The Institute encourages research in certain scientific areas through requests for applications, Notices of Special Interest, and program announcements. NIGMS also participates in the NIH Loan Repayment Program (LRP) to enhance the quality of the scientific community through incentives for biomedical and behavioral researchers and trainees. Eligibility criteria and other details can be found on our LRP page .
Which Research Grant is Right for Me? This decision tree will help identify potential fit to one or more notices of funding opportunity (NOFOs) NIGMS generally uses to fund research project grants (RPGs), including R35, R16, R15, and R01. See Something, Say Something Concerned about grant scams, fraud, research misconduct, harassment, foreign interference, or peer review violations?
Learn about these different forms of misconduct and get in touch.
Submitting an Application Research Programs and Contacts Grant Application and Review Process Electronic Grant Submission Summary Statement and Just-In-Time Actions: Research Grants, Fellowships, and TWD Talking to NIH Staff About Your Application and Grant Considerations for Multiple Principal Investigator (MPI) Applications Data Management and Sharing Plan Expectations for NIGMS Grantees Message to NIGMS Investigators Attribution of NIH/NIGMS Support Budget and Administrative Issues Monitoring and Progress Reports Research Using Human Subjects or Specimens Data Management and Sharing Plan Expectations for NIGMS Grantees NIGMS Funding Trends Analyses (including percentiles and success rates) NIGMS Capacity Building Programs - IDeA , SEPA , SCORE , NARCH NIGMS Programs in Specific Science Areas Search Funded Projects Using NIH RePORTER
According to the current listing, eligibility includes: Eligible applicants include institutions of higher education, non-profit organizations, hospitals, and other research organizations. Principal Investigators typically need a doctoral degree. Confirm the full requirements in the official notice before applying.
The current listing shows varies (e.g., $392,500, $631,034). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Project Grant (Multiple awards found related to ribosome biogenesis) is funded by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This grant aims to advance gene-based therapies for ultra-rare neurological and neuromuscular disorders. This initiative focuses on IND-enabling studies and supports the development of innovative therapeutics with proven biological rationale.
Focused Technology Research and Development (R01 Clinical Trial Not Allowed) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) supports projects relevant to the NIGMS mission that focus solely on the development of technologies with the potential to enable the acquisition of biomedical knowledge. The project outcome is a working prototype of the technology.
R21 Exploratory Technology Development is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This program supports exploratory technology development projects relevant to the NIGMS mission. It is suitable for novel, high-risk projects, and preliminary data is not required. The project outcome is a proof of concept study.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article